SynthesisOncoimmunology2021

Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.

Lifang Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.